<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525330</url>
  </required_header>
  <id_info>
    <org_study_id>0104-003</org_study_id>
    <nct_id>NCT00525330</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ActivX Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyorin Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ActivX Biosciences, Inc.</source>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of chronic therapy with KRP-104, a novel DPP-IV inhibitor,
      in patients with Type 2 Diabetes on stable metformin therapy. In addition, an estimate of how
      much of the HbA1c response is attributable to nocturnal coverage will be explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this trial is to demonstrate the hemoglobin A1c (HbA1c)-lowering effects of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone.</measure>
    <time_frame>12-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the fasting plasma glucose (FPG)-lowering effect of KRP-104 in patients with type 2 diabetes inadequately controlled on metformin alone;</measure>
    <time_frame>12-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare effects of once daily (QD) dosing versus twice daily (BID) dosing of KRP-104 on HbA1c and FPG</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of KRP-104 on post-prandial glucose dynamics and insulin sensitivity (homeostasis model index [HOMA-β]) in the setting of a Meal Tolerance Test(MTT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes from pre-prandial to 2-hour post-prandial glucose, active GLP-1, insulin summarized by treatment group from Week 0 to Week 5 and Week 12. Percent change in 2-hour post-prandial glucose summarized by treatment group from Week 0 to Week 5 and Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of KRP-104;</measure>
    <time_frame>Daily for 12 weeks to 2 weeks post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>KRP-104 120 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KRP-104 60 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRP-104 QD Drug: Placebo Drug: Metformin</intervention_name>
    <description>KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal</description>
    <arm_group_label>KRP-104 120 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Drug: Metformin</intervention_name>
    <description>Two tablets 15 to 30 minutes before each meal, morning and evening.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRP-104 BID Drug: Placebo Drug: Metformin</intervention_name>
    <description>KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.</description>
    <arm_group_label>KRP-104 60 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 70 years, inclusive;

          2. Males and females of non-childbearing potential;

          3. Diagnosis of type 2 diabetes mellitus according; and

          4. On a stable dose of metformin monotherapy at randomization (can be on other oral
             therapies or naive at study entry

        Exclusion Criteria:

          1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent
             hypoglycemia;

          2. History or presence of alcoholism or drug abuse

          3. Typical consumption of ≥10 drinks of alcohol weekly;

          4. Presence of any of the following conditions:

               -  Significant renal impairment (glomerular filtration rate &lt;60 mL/min [to be
                  calculated by the central laboratory]);

               -  Diabetic retinopathy;

               -  Diabetic gastroparesis;

               -  Active liver disease (other than asymptomatic nonalcoholic fatty liver disease),
                  cirrhosis, or symptomatic gallbladder disease;

          5. Uncontrolled high blood pressure;

          6. History or evidence of cardiovascular or pulmonary disease

          7. Must meet other laboratory and Medical History clinical criteria. Please contact
             recruitment center for referrals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Orloff</last_name>
    <role>Study Chair</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tufail Syed</last_name>
    <role>Study Chair</role>
    <affiliation>Medpace India</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <disposition_first_submitted>June 7, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 7, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 21, 2011</disposition_first_posted>
  <last_update_submitted>August 14, 2013</last_update_submitted>
  <last_update_submitted_qc>August 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

